Joining up Germany’s medtech strategy
This article was originally published in Clinica
Executive Summary
The important role that SMEs (“KMUs” in Germany) play in developing medical technologies was acknowledged last week by Germany’s education and research ministry (BMBF) when it granted €10 million annually to a research funding project for small companies.
You may also be interested in...
Medtech Under Pressure? German Industry Urges Realistic Patient Safety And Innovation Balance
Meaningful medtech advances that have the potential to revolutionize patient care cannot happen by eliminating risk entirely, but it’s a balance that European stakeholders are failing to achieve consistently. This is so in Germany too, says the BVMed industry association, with negative consequences for those at the sharp end of innovation – the SMEs and start-ups who originate a vast proportion of medtech advances.
Germany – Still Europe's Stand-Out Medtech Innovation Market
Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.